Theraclion (ENXTPA:ALTHE) - Share price, News & Analysis

ALTHE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

ALTHE Stock Overview

Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system.

Rewards

Revenue is forecast to grow 81.24% per year

Earnings have grown 14.7% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have meaningful revenue (€2M)

Does not have a meaningful market cap (€34M)

Theraclion Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Theraclion
Historical stock prices
Current Share Price	€1.20
52 Week High	€2.28
52 Week Low	€0.91
Beta	0.78
1 Month Change	-5.14%
3 Month Change	-14.29%
1 Year Change	-29.20%
3 Year Change	-9.43%
5 Year Change	-78.18%
Change since IPO	-90.88%

Shareholder Returns

	ALTHE	FR Medical Equipment	FR Market
7D	-4.8%	1.1%	-1.5%
1Y	-29.2%	-6.3%	-18.8%

Return vs Industry: ALTHE underperformed the French Medical Equipment industry which returned -5.9% over the past year.

Return vs Market: ALTHE underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is ALTHE's price volatile compared to industry and market?
ALTHE volatility
ALTHE Average Weekly Movement	7.0%
Medical Equipment Industry Average Movement	7.1%
Market Average Movement	6.0%
10% most volatile stocks in FR Market	10.2%
10% least volatile stocks in FR Market	3.5%

Stable Share Price: ALTHE is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ALTHE's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2004	n/a	David Caumartin	https://www.theraclion.com

Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient’s skin and optimizes the image quality. The company was founded in 2004 and is based in Malakoff, France.

Theraclion Fundamentals Summary

How do Theraclion's earnings and revenue compare to its market cap?
ALTHE fundamental statistics
Market Cap	€34.45m
Earnings (TTM)	-€3.76m
Revenue (TTM)	€1.68m

20.5x

P/S Ratio

-9.2x

P/E Ratio

Is ALTHE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALTHE income statement (TTM)
Revenue	€1.68m
Cost of Revenue	€2.88m
Gross Profit	-€1.19m
Other Expenses	€2.57m
Earnings	-€3.76m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.13
Gross Margin	-70.78%
Net Profit Margin	-223.28%
Debt/Equity Ratio	0.0%

How did ALTHE perform over the long term?

See historical performance and comparison

Valuation

Is Theraclion undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

In this section, we usually try to help investors determine whether Theraclion is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Theraclion has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.

Future Growth

How is Theraclion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

81.2%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALTHE's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if ALTHE's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ALTHE's revenue (81.2% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ALTHE's revenue (81.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALTHE's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Theraclion performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

14.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALTHE is currently unprofitable.

Growing Profit Margin: ALTHE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ALTHE is unprofitable, but has reduced losses over the past 5 years at a rate of 14.7% per year.

Accelerating Growth: Unable to compare ALTHE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALTHE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).

Return on Equity

High ROE: ALTHE has a negative Return on Equity (0%), as it is currently unprofitable.

Financial Health

How is Theraclion's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if ALTHE's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if ALTHE's short term assets cover its long term liabilities.

Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate ALTHE's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if ALTHE's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALTHE has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALTHE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is Theraclion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALTHE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALTHE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALTHE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALTHE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALTHE has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average management tenure

CEO

David Caumartin

7.67yrs

Tenure

€293,758

Compensation

Mr. David Caumartin has been the Chief Executive Officer of Theraclion SA since September 30, 2014. Mr. Caumartin is healthcare industry specialist with experience at GE Healthcare, covering Europe, Middle...

CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the French market.

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: ALTHE's management team is seasoned and experienced (7.7 years average tenure).

Board Members

Experienced Board: ALTHE's board of directors are considered experienced (3.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 72.7%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31